Skip to main content
Erschienen in: Rheumatology International 2/2013

01.02.2013 | Original Article

Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA

verfasst von: Youjun Xiao, Liuqin Liang, Yunfeng Pan, Fan Lian, Long Li, Haobo Lin, Di Fu, Jinjin Fan, Xiuyan Yang, Lin Sun, Hanshi Xu

Erschienen in: Rheumatology International | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

To investigate the effect of simvastatin on the migration and invasion of fibroblast-like synoviocytes (FLS) from patients with rheumatoid arthritis (RA) and its cellular signal mechanisms, FLS from active RA patients were stimulated with 3 % FBS or GM-CSF in the presence or absence of simvastatin. Cells migration and invasion in vitro were measured by the Boyden chamber method. RhoA activity was assessed by a pull-down assay. Matrix metalloproteinases-2 (MMP-2) activity was evaluated by zymography. Simvastatin inhibits FBS- or GM-CSF-induced migration in a dose-dependent manner by RA FLS, and this inhibitory effect is independent of cell apoptosis. We also found that simvastatin suppressed in vitro invasion, adhesion, MMP-2 activity, cytoskeletal reorganization and RhoA activation. Furthermore, mevalonate or GGPP treatment reversed the inhibitory effect of simvastatin not only on migration and invasion in vitro but also on RhoA activation, and inhibition of RhoA by specific siRNA transfection reduced migration, adhesion and invasion of RA FLS. This study shows that simvastatin reduces RA FLS migration and invasion through the prevention of protein geranylgeranylation and RhoA activation. These findings provide a novel evidence that statin may be benefit for preventing RA arthritic destruction, and also indicate that RhoA may be a new target for the modulation of RA FLS migration and invasion.
Literatur
1.
Zurück zum Zitat Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef
2.
Zurück zum Zitat Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61:(Suppl 2):ii84–ii86 Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61:(Suppl 2):ii84–ii86
3.
Zurück zum Zitat Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H (2005) The role of the T cell in autoimmune inflammation. Arthritis Res Ther 7(Suppl 2):S4–S14PubMedCrossRef Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H (2005) The role of the T cell in autoimmune inflammation. Arthritis Res Ther 7(Suppl 2):S4–S14PubMedCrossRef
4.
Zurück zum Zitat Ma Y, Pope RM (2005) The role of macrophages in rheumatoid arthritis. Curr Pharm Des 11:569–580PubMedCrossRef Ma Y, Pope RM (2005) The role of macrophages in rheumatoid arthritis. Curr Pharm Des 11:569–580PubMedCrossRef
5.
Zurück zum Zitat Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR (1997) Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94:10895–10900PubMedCrossRef Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR (1997) Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94:10895–10900PubMedCrossRef
6.
Zurück zum Zitat Roivainen A, Jalava J, Pirila L, Yli-Jama T, Tiusanen H, Toivanen P (1997) H-ras oncogene point mutation in arthritic synovium. Arthritis Rheum 40:1636–1643PubMedCrossRef Roivainen A, Jalava J, Pirila L, Yli-Jama T, Tiusanen H, Toivanen P (1997) H-ras oncogene point mutation in arthritic synovium. Arthritis Rheum 40:1636–1643PubMedCrossRef
7.
Zurück zum Zitat Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S (2005) Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1:102–110PubMedCrossRef Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S (2005) Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1:102–110PubMedCrossRef
8.
Zurück zum Zitat Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T (2006) Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45:669–675PubMedCrossRef Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T (2006) Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45:669–675PubMedCrossRef
9.
Zurück zum Zitat Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE et al (1996) Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149:1607–1615PubMed Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE et al (1996) Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149:1607–1615PubMed
10.
Zurück zum Zitat Pap T, Meinecke I, Muller-Ladner U, Gay S (2005) Are fibroblasts involved in joint destruction? Ann Rheum Dis 64(Suppl 4):iv52–iv54 Pap T, Meinecke I, Muller-Ladner U, Gay S (2005) Are fibroblasts involved in joint destruction? Ann Rheum Dis 64(Suppl 4):iv52–iv54
11.
Zurück zum Zitat Lefèvre S, Knedlal A, Tenniel C, Kampmann A, Wunrau C, Dinser R et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420PubMedCrossRef Lefèvre S, Knedlal A, Tenniel C, Kampmann A, Wunrau C, Dinser R et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420PubMedCrossRef
12.
Zurück zum Zitat Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358–370PubMedCrossRef Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358–370PubMedCrossRef
14.
15.
Zurück zum Zitat Scita G, Tenca P, Frittoli E (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J 19:2393–2398PubMedCrossRef Scita G, Tenca P, Frittoli E (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J 19:2393–2398PubMedCrossRef
16.
Zurück zum Zitat Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611PubMedCrossRef Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611PubMedCrossRef
17.
Zurück zum Zitat McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRef McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRef
18.
Zurück zum Zitat Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritis. J Rheumatol 32:2095–2101PubMed Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritis. J Rheumatol 32:2095–2101PubMed
19.
Zurück zum Zitat Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530PubMed Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530PubMed
20.
Zurück zum Zitat Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y et al (2006) RhoA-mediated, tumor necrosis factor α-induced activation of NF-κB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54:3441–3451PubMedCrossRef Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y et al (2006) RhoA-mediated, tumor necrosis factor α-induced activation of NF-κB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54:3441–3451PubMedCrossRef
21.
Zurück zum Zitat Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al (2005) Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516:282–289PubMedCrossRef Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al (2005) Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516:282–289PubMedCrossRef
22.
Zurück zum Zitat Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M (2007) Effects of pravastatin in murine collagen induced arthritis. Rheumatol Int 27:631–639PubMedCrossRef Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M (2007) Effects of pravastatin in murine collagen induced arthritis. Rheumatol Int 27:631–639PubMedCrossRef
23.
Zurück zum Zitat Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Sahai A et al (2002) 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors prevent high glucose induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 99:8301–8305PubMedCrossRef Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Sahai A et al (2002) 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors prevent high glucose induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 99:8301–8305PubMedCrossRef
24.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
25.
Zurück zum Zitat Wang AZ, Chen JM, Fisher GW, Wang JC, Diamond HS (1994) Improved in vitro models for assay of rheumatoid synoviocyte chemotaxis. Clin Exp Rheumatol 12:293–299PubMed Wang AZ, Chen JM, Fisher GW, Wang JC, Diamond HS (1994) Improved in vitro models for assay of rheumatoid synoviocyte chemotaxis. Clin Exp Rheumatol 12:293–299PubMed
26.
Zurück zum Zitat Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586PubMedCrossRef Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586PubMedCrossRef
27.
Zurück zum Zitat Litinsky I, Golan I, Yaron M, Yaron I, Caspi D, Elkayam O (2009) Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J 3:35–40PubMedCrossRef Litinsky I, Golan I, Yaron M, Yaron I, Caspi D, Elkayam O (2009) Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J 3:35–40PubMedCrossRef
28.
Zurück zum Zitat Yokota K, Miyoshi F, Miyazaki T, Sato K, Yoshida Y, Asanuma Y et al (2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35:193–200PubMed Yokota K, Miyoshi F, Miyazaki T, Sato K, Yoshida Y, Asanuma Y et al (2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35:193–200PubMed
29.
Zurück zum Zitat John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14–23PubMedCrossRef John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14–23PubMedCrossRef
30.
Zurück zum Zitat McMahon M, Brahn E (2008) Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opin Investig Drugs 17:1213–1224PubMedCrossRef McMahon M, Brahn E (2008) Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opin Investig Drugs 17:1213–1224PubMedCrossRef
31.
Zurück zum Zitat Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A et al (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7:e1000336PubMedCrossRef Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A et al (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7:e1000336PubMedCrossRef
32.
Zurück zum Zitat Wahane VD, Kumar VL (2010) Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 61:329–333PubMedCrossRef Wahane VD, Kumar VL (2010) Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 61:329–333PubMedCrossRef
33.
Zurück zum Zitat Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H et al (2010) Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 55:39–48PubMedCrossRef Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H et al (2010) Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 55:39–48PubMedCrossRef
34.
Zurück zum Zitat Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159:1294–1303PubMedCrossRef Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159:1294–1303PubMedCrossRef
35.
Zurück zum Zitat Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S et al (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 48:233–242PubMedCrossRef Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S et al (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 48:233–242PubMedCrossRef
36.
Zurück zum Zitat Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW (2009) Statins alter neutrophil migration by modulating cellular Rho activity–a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 85:186–193PubMedCrossRef Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW (2009) Statins alter neutrophil migration by modulating cellular Rho activity–a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 85:186–193PubMedCrossRef
37.
Zurück zum Zitat Fromigué O, Hamidouche Z, Marie PJ (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283:30549–30556PubMedCrossRef Fromigué O, Hamidouche Z, Marie PJ (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283:30549–30556PubMedCrossRef
38.
39.
Zurück zum Zitat Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM (2007) Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum 56:2512–2522PubMedCrossRef Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM (2007) Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum 56:2512–2522PubMedCrossRef
40.
Zurück zum Zitat Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258PubMedCrossRef Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258PubMedCrossRef
Metadaten
Titel
Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA
verfasst von
Youjun Xiao
Liuqin Liang
Yunfeng Pan
Fan Lian
Long Li
Haobo Lin
Di Fu
Jinjin Fan
Xiuyan Yang
Lin Sun
Hanshi Xu
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 2/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2383-7

Weitere Artikel der Ausgabe 2/2013

Rheumatology International 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.